Evidence map›Paper›PMID 32764469›Full record

ArticleCancers2020

Phenotypic and Functional Characterization of NK Cells in αβT-Cell and B-Cell Depleted Haplo-HSCT to Cure Pediatric Patients with Acute Leukemia.

Raffaella Meazza, Michela Falco, Fabrizio Loiacono, Paolo Canevali, Mariella Della Chiesa, Alice Bertaina, Daria Pagliara, Pietro Merli, Valentina Indio, Federica Galaverna and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Raffaella MeazzaLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-0242-3157
Michela FalcoLaboratory of Clinical and Experimental Immunology, Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Fabrizio LoiaconoLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Paolo CanevaliLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Mariella Della ChiesaDepartment of Experimental Medicine, Centre of Excellence for Biomedical Research, University of Genoa, 16132 Genoa, Italy.
Alice BertainaDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Daria PagliaraDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Pietro MerliDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Valentina IndioGiorgio Prodi Interdepartmental Center for Cancer Research-CIRC, University of Bologna, 40138 Bologna, Italy.ORCID 0000-0002-8854-3821
Federica GalavernaDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Mattia AlgeriDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Francesca MorettaDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Natalia Colomar-CarandoLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Letizia MuccioDepartment of Experimental Medicine, University of Genoa, 16132 Genoa, Italy.
Simona SivoriDepartment of Experimental Medicine, Centre of Excellence for Biomedical Research, University of Genoa, 16132 Genoa, Italy.ORCID 0000-0003-1279-1172
Andrea PessionGiorgio Prodi Interdepartmental Center for Cancer Research-CIRC, University of Bologna, 40138 Bologna, Italy.
Maria Cristina MingariLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.
Lorenzo MorettaDepartment of Immunology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Alessandro MorettaDepartment of Experimental Medicine, Centre of Excellence for Biomedical Research, University of Genoa, 16132 Genoa, Italy.
Franco LocatelliDepartment of Hematology/Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, 00146 Rome, Italy.
Daniela PendeLaboratory of Immunology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, 16132 Genoa, Italy.ORCID 0000-0003-1565-451X
Bambino Gesù Children's Hospital · ITOspedale Policlinico San Martino · ITUniversity of Genoa · ITUniversity of Bologna · ITIstituto Giannina Gaslini · IT

Funding

Accelerator Award 2017 INCARAssociazione Italiana per la Ricerca sul Cancro 16764Associazione Italiana per la Ricerca sul Cancro 19920Associazione Italiana per la Ricerca sul Cancro 20312Associazione Italiana per la Ricerca sul Cancro 21147Associazione Italiana per la Ricerca sul Cancro 21724Horizon 2020 MSCA-ITN-2017-765104-MATURE-NKMinistero della Salute 5xmille 2015 and 2016Ministero della Salute RC-2019 IRCCS Ospedale Policlinico San MartinoMinistero della Salute RC-2020 OPBGMinistero della Salute RF-2016-02364388Ministero dell'Istruzione, dell'Università e della Ricerca PRIN 2017WC8499_004
6 · The paper itself

Abstract

NK cells can exert remarkable graft-versus-leukemia (GvL) effect in HLA-haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Here, we dissected the NK-cell repertoire of 80 pediatric acute leukemia patients previously reported to have an excellent clinical outcome after αβT/B-depleted haplo-HSCT. This graft manipulation strategy allows the co-infusion of mature immune cells, mainly NK and γδT cells, and hematopoietic stem cells (HSCs). To promote NK-cell based antileukemia activity, 36/80 patients were transplanted with an NK alloreactive donor, defined according to the KIR/KIR-Ligand mismatch in the graft-versus-host direction. The analysis of the reconstituted NK-cell repertoire in these patients showed relatively high proportions of mature and functional KIR

Indexed as

haploidentical hematopoietic stem cell transplantation (HSCT)human cytomegalovirus (HCMV)killer Ig-like receptors (KIR)NK alloreactivityNK cellspediatric acute leukemia

Identifiers

PMID32764469
PMCPMC7463940
OpenAlexW3046974375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.